PMV Pharma reports Q3 2025 net loss of $21.1M; highlights 34% ORR with rezatapopt in PYNNACLE study

PMV Pharmaceuticals, Inc.

2025-Q3 EPS reported -$1.14 vs consensus -$0.41 ▼ miss (-177.6%)

Cash, cash equivalents, and marketable securities of $129.3M as of Sept 30, 2025; cash runway to end of Q1 2027.
Overall response rate of 34% (35/103 patients) in Phase 2 PYNNACLE study; 46% ORR in ovarian cancer cohort with median duration of response of 8.0 months.
Rezatapopt NDA submission for platinum-resistant/refractory ovarian cancer planned for Q1 2027.
Net loss for Q3 2025 was $21.1M vs $19.2M in Q3 2024, driven by increased R&D costs of $18.2M.
R&D expenses increased to $18.2M from $16.9M due to advancement of rezatapopt program; G&A decreased to $4.3M from $4.9M.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.